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Abstract: In this study two monocytic leukemia cell lines, U937 and THP-1 cells, were 
used to investigate the anti-proliferation effects caused by ponicidin. Cell viability was 
measured by an MTT assay. Cell apoptosis was assessed by flow cytometry as well as 
DNA fragmentation analysis. Cell morphology was observed using an inverted 
microscope and Hoechst 33258 staining. RT-PCR and Western blot analysis were used to 
detect survivin as well as Bax and Bcl-2 expressions after the cells were treated with 
different concentrations of ponicidin. The results revealed that ponicidin could inhibit the 
growth of U937 and THP-1 cells significantly by induction of apoptosis. The suppression 
was in both time- and dose-dependent manner. Marked morphological changes of cell 
apoptosis were observed clearly after the cells were treated with ponicidin for 48~72 h. 
RT-PCR and Western blot analysis demonstrated that both survivin and Bcl-2 
expressions were down-regulated remarkably while Bax expression remained constant 
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before and after apoptosis occurred. We therefore conclude that ponicidin has significant 
anti-proliferation effects by inducing apoptosis on leukemia cells in vitro, downregulation 
of survivin as well as Bcl-2 expressions may be the important apoptosis inducing 
mechanisms. The results suggest that ponicidin may serve as potential therapeutic agent 
for leukemia. 
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1. Introduction 
 
Ponicidin, a diterpenoid compound, is extracted and purified from the traditional Chinese herbs 
Rabdosia rubescens or Isodon japonicas [1, 2]. Ponicidin has been reported to have a variety of 
biological effects such as immunoregulatory and anti-inflammatory functions as well as anti-viral 
functions especially in the upper respiratory tract infection [3]. Recent laboratory data suggest that 
ponicidin is a very effective anti-tumor agent, with profound effects on a number of cancer cells such 
as human leukemia cell line K562, human breast cancer cell line Bcap37, human gastric cancer cell 
line BGC823, human urinary bladder cancer cell lineBIU87, and Hela cell lines [1-4]. Later studies 
have shown that ponicidin can promote the cell-killing activity of antiherpes prodrugs acyclovir (ACV) 
and ganciclovir (GCV) in human cancer cells expressing herpes simplex virus thymidine kinase 
(HSV-TK), and the combined use of ponicidin with GCV or ACV may produce high cytotoxicity in 
viral TK-expressing cancer cells and lead to a rapid and enhanced tumor elimination in vivo [5]. New 
data have demonstrated that ponicidin can inhibit the growth and metastasis of prostate cancer due to 
its significant antiangiogenic activity [6]. 
Although ponicidin has been proved to be very effective in a variety of malignancies, many of its 
anti-tumor mechanisms remain to be demonstrated. Up to date, no detailed data are available about the 
role and mechanisms of ponicidin in leukemia cells. In order to understand the roles of ponicidin in 
leukemia cells and possible clinical application of ponicidin in leukemia therapy, we have investigated 
the effects of different concentrations of ponicidin on cell viability and apoptosis on monocytic 
leukemia cells in vitro.  
 
2. Experimental 
 
2.1. Main reagents 
 
Ponicidin was kindly provided by Prof. XL Pan. Hoechst 33258 was purchased from Sigma 
Company. The antibodies used in this study, anti-Survivin, anti-Bcl-2 and anti-Bax, were purchased 
from Santa Cruz Company (Germany). TRIZOL was from GIBCO (USA), and reverse transcriptional 
kit was from MBI (USA); PCR primers (shown in Table 1) were synthesized by Shanghai Shenggong 
Company (China). 
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Table 1. The PCR primers used in this study. 
β-actin mRNA (243 bp) 
Sense primer  5’-CTTCTACAATGAGCTGCGTG-3’ 
Anti-sense primer:  5’-TCATGAGGTAGTCAGTCAGG -3’ 
Survivin mRNA ( 393 bp ) 
Sense primer :,  5’-CTTTCTCAAGGACCACCGCATC-3’ 
Anti-sense primer :  5’-CAATCCATGGCAGCCAGCTGC-3’ 
bcl-2 mRNA ( 478 bp ) : 
Sense primer:  5’-CTACGAGTGGGATGCGGGAGATG-3’ 
Sense primer :  5’-GGTTCAGGTACTCAGTCATCCACAG-3’ 
Bax mRNA ( 258 bp ) : 
Sense primer:  5’-ACCAA GAA GCTGA GCGA GTGTC-3’ 
Anti-sense primer:  5’-TGTCCA GCCCA TGA TGGTTC-3’ 
 
2.2. Cell culture   
 
U937 and THP-1 cells were provided by the Central Laboratory of the Sun Yat-sen University 
Cancer Center. Normal peripheral blood monocytes (NPBMs) were isolated from healthy volunteers 
after obtaining informed consent by means of Ficoll density gradient centrifugation (specific gravity, 
1.077; Shanghai Reagent Factory, Shanghai, China).Cells were cultured in RPMI-1640 medium 
supplemented with 10% fetal calf serum (FBS), 100U/mL penicillin and l00 µg/mL streptomycin, in a 
humidified incubator with 5% CO2  at 37 °C. All the cells were passaged twice weekly and routinely 
examined for mycoplasma contamination. Cells in logarithmic growth phase were used for further 
experiments. 
 
2.3. Cell viability assay 
 
The viability of the cells was assessed by MTT assay, which is based on the reduction of MTT by 
the mitochondrial dehydrogenase of intact cells to a purple formazan product. Briefly, U937 and 
THP-1 cells as well as NPBMs
 in logarithmic growth-phase were collected, and 2 × 10
5 cells/well were 
dispensed within 96-well culture plates in 100 mL volumes. Then different concentrations of ponicidin 
(10, 20, 30, 40 and 50 μmol/L) were put in different wells. Every one of the concentrations above was 
regarded as one treated group while there was no ponicidin in the control group. Each of the treated or 
control group contained six parallel wells. Culture plates were then incubated for 0, 24, 48 and 72 
hours prior to the addition of tetrazolium reagent. MTT working solution was prepared as follows: 5 
mg MTT/mL PBS was sterile by being filtered with 0.45 μm filter units. Each of the above cultured 
wells was added 20 μL of MTT working solution and then incubated continuously for 4 hours. The 
water insoluble formazan was formed during incubation and it was solublized by adding solublization 
agent to each well. Amount of formazan was determined by measuring the absorbance at 540 nm using 
an ELISA plate reader. 
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2.4. Flow cytometry (FCM) detection 
 
For FCM analysis, U937 and THP-1 cells treated with different concentrations of ponicidin for 
different times were collected, pelleted, washed with PBS, and resuspended in PBS containing 20 
mg/L PI and 1g/L ribonuclease A. 1 × 10
6 fixed cells were examined per experimental condition by 
flow cytometry. The percentage of degraded DNA was determined by the number of cells displaying 
subdiploid ( sub-G1) DNA divided by the total number of cells examined. 
 
2.5. Detection of mRNA expressions using RT-PCR 
 
The expressions of Survivin as well as Bcl-2 and Bax in U937 and THP-1 cells were examined by 
RT-PCR before and after the cells were treated with different concentrations of ponicidin for 72 h. The 
total RNA was extracted by using TRIZOL reagent according to the instructions described on the kit, 
which was certified to be suitable for RT-PCR by using agrose gel electrophoresis. First-stranded 
cDNA was synthesized using 5 μg total RNA by RT-PCR kit. The related PCR primers listed in Table 1 
were used to produce the correlated products respectively. 
As an internal control, the expression of β-actin was detected. The PCR reaction for β-actin cDNAs 
was performed with 30 amplification cycles and the reaction conditions were: denaturation at 94 °C for 
1 min, annealing at 53 °C for 2 min, and extension at 72 °C for 3 min. The PCR reactions for both 
survivin and Bcl-2/Bax cDNAs were performed with 40 amplification cycles respectively as follows: 
(1) survivin and Bcl-2: denaturation at 94 °C for 45 s, annealing at 61 °C for 1 min, and extension at 
72 °C for 1 min). (2) Bax: denaturation at 94 °C for 45 s, annealing at 58 °C for 1 min, and extension 
at 72 °C for 1 min. All of the above PCR reactions were incubated in an automatic heat-block(Model 
PJ 2000 DNA Thermal Cycler. The PCR products were then run on 1.5% agarose gel in TAE buffer for 
20-30 min respectively and then visualized by ethidium bomide staining. 
 
2.6. Hoechst 33258 staining 
 
The morphology of U937 and THP-1 cells exposed to ponicidin for different time was observed 
firstly under inverted microscope. Then Hoechst 33258 staining was used to observe the apoptotic 
morphology. Cells were fixed with 4% formaldehyde in phosphate buffered saline (PBS) for 10 min, 
stained by Hoechst 33258 (10 mg/L) for one hour, and then subjected to fluorescence microscopy. 
After treatment with ponicidin, the morphologic changes including reduction in the volume and 
nuclear chromatin condensation were observed. 
 
2.7. DNA fragmentation assay 
 
Apoptosis was confirmed by detection of fragmentation of chromosomal DNA with the classic 
DNA ladder method. Briefly, 2 × 10
6 cells were immersed in cytolysis buffer (Tris-HCL 1 mmol/L pH 
8.0, edetic acid 10 mmol/L pH 8.0, proteinase K 200 mg/L, 0.5 % SDS) and incubated for 3 h at 50 °C. 
DNA was extracted with phenol-chloroform, precipitated in 1/10 volume of NaOAc 2 mol/L and 2 
volumes of ethanol at -20 °C overnight, recovered by centrifugation at 1000 × g for 30 min at 4 °C, Int. J. Mol. Sci. 2008, 9                 
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and then resuspended in TE buffer. RNase A was then added at a concentration of 200 mg/L, then the 
treated extract was incubated at 37 °C for 30 min and electrophoresed on a 1.2% agarose gel. 
 
2.8. Western blot analysis 
 
For Western blotting, cells were washed with ice-cold PBS twice and lysed for 30 min at 4 °C, then 
debris was removed by centrifugation for 15 min at 15,000×g at 4 °C, and equivalent amounts of 
protein were separated by 10 % SDS-PAGE and transferred onto nitrocellulose filters. The filters were 
first stained to confirm uniform transfer of all samples and then incubated in blocking solution for 2 h 
at room temperature. The filters were reacted firstly with the following antibodies: anti-survivin, 
anti-bcl and anti-Bax at a dilution of 1:1000 for 2 h, followed by extensive washes with PBS twice and 
TBST twice. Filters were then incubated with 1:1000 horseradish peroxidase-conjugated secondary 
antibodies for 1 h, washed with TBST and developed using the Super Signal West Pico Kit. As an 
internal control, β-actin was detected with anti-β-actin antibodies. 
 
2.9. Statistical analysis 
 
All experiments were performed in triplicates and the results were expressed as mean ± SD. 
Statistical analyses were performed with t-test using SAS 6.12 software. 
 
3. Results 
 
3.1. Cell viability 
 
To investigate the growth inhibition effects of ponicidin on leukemia U937 and THP-1 cells as well 
as normal peripheral blood monocytes (NPBMs), the cells were treated with various concentrations of 
ponicidin for 0, 24, 48 and 72 h. As shown in Figure 1, ponicidin (over 10 μmol/L) had significant 
growth inhibition effects on the two kinds of leukemia cells in a dose-and time-dependent manner, 
while there was no significant cytotoxicity of ponicidin on NPBMs compared to the target leukemia 
cells. The two kinds of leukemia cells showed somewhat different sensitivity to different 
concentrations of ponicidin measured by the MTT test, with the THP-1 cells being a bit more sensitive 
to ponicidin, compared with U937 cells. Cell viability was decreased remarkably after the cells were 
treated with 50 μmol/L ponicidin for 72 h. 
 
3.2. Flow cytometry analysis 
 
To show whether the growth inhibition induced by ponicidin in U937 and THP-1 cells was caused 
by induction of apoptosis, the cells were stained with PI and analyzed by FCM. As shown in Figure 2, 
the percentage of sub-G1 cells in U937 and THP-1 cells was increased in a dose- and time dependent 
manner. Along with the enhancement of cell growth inhibition, apoptotic cells gradually increased and 
the percentage of sub-G1 cells of both U937 and THP-1 cells reached up to over 60% when the cells 
were treated with 40 μmol/L ponicidin for 72 h. Flow histogram of sub-G1 cells were also observed Int. J. Mol. Sci. 2008, 9                 
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clearly after the cells were treated by 50μmol/L ponicidin for different times. As shown in Figure 3, the 
sub-G1 percentage of both U937 and THP-1 cells gradually increased in a time-dependent manner. 
 
Figure 1. Cell viability caused by ponicidin. 
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After the cells were treated with different concentrations of ponicidin for 24, 48 and 72 h, the cell 
viability was determined by MTT assay as described in the Methods. Experiments were done in 
triplicate.Values represent mean (±SD) cell viability as a percentage of untreated control samples. 
 
Figure 2. Cell apoptosis caused by ponicidin. 
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After the cells were treated with different concentrations of ponicidin for 24, 48 and 72 h, apoptotic 
rate was detected as described in the Methods. Cells were stained with PI and then analyzed by FCM, 
the percentage of sub-G1 cells in the two kinds of cell lines was increased in both time- and 
dose-dependent manner especially treated with 40 μmol/L ponicidin for 72 h, the percentage of sub-G1 Int. J. Mol. Sci. 2008, 9                 
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cells of both U937 and THP-1 cells was over 50%. The experiments were repeated three times and the 
results were presented as mean ±SD. 
 
Figure 3. Flow histogram of sub-G1 cells. 
 
 
After the cells were treated by 50 μmol/L ponicidin for different times (24, 48 and 72 h), flow 
histograms of sub-G1 cells were detected by FCM as described in the Methods. The percentage of 
sub-G1 cells (shown by the ‘arrow’) was gradually increased in a time-dependent manner in both 
THP-1 and U937 cells. After treatment of 72 h, the percentage of sub-G1 cells was over 50%. 
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3.3. Expression of apoptosis related genes 
 
After treatment with 40 μmol/L ponicidin for 48 and 72 h, the mRNA expressions of both Survivin 
and Bcl-2 were down-regulated while mRNA expression of Bax remained constant (Figure 4 A). 
Likely, the protein levels of Survivin and Bcl-2 were down-regulated and no variation of Bax protein 
expression was observed concurrently examined by Western blotting when apoptosis occurred (Figure 4B). 
    
Figure 4. Expression of pro-and anti-apoptotic genes detected by RT-PCR and Western 
blot. Expression of pro-and anti-apoptotic genes was detected by RT-PCR (A) and Western 
blot (B) after treatment with 40 µmol/L ponicidin for 48 and 72 h. Both mRNA and protein 
levels of Survivin and Bcl-2 were down-regulated while the mRNA expression and protein 
level of Bax remained constant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4. Hoechst 33258 staining 
 
After cells treated with 40 μmol/L ponicidin for 48 and 72 h, marked morphological changes of 
cell apoptosis such as condensation of chromatin and nuclear fragmentations were found clearly using 
Hoechst 33258 staining (Fig.5). Apoptotic cells gradually increased in time-dependent manner in both 
U937 and THP-1 cells. 
 
3.5. DNA fragmentation analysis 
 
To observe ponicidin induced apoptosis in monocytic leukemia cells, the integrity of DNA was 
assessed by agarose gel electrophoresis after the cells were treated for 48 and 72 h. As shown in Fig.6, 
incubation of U937 and THP-1 cells with 40 μmol/L ponicidin elicited a characteristic “ladder” of 
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DNA fragments representing integer multiples of the internucleosomal DNA length (about 180~200 
bp). DNA ladder was observed in a dose-manner (Fig. 6).   
 
Figure 5. Apoptosis observed by Hoechst 33258 staining (200×). After the cells were 
treated with 40 µmol/L ponicidin, Hoechst 33258 staining was used to observe the 
morphological changes of cell apoptosis. Morphological changes of cell apoptosis such as 
condensation of chromatin and nuclear fragmentations were found clearly. A: Control; B: 
Cells treated for 48 h; C: Cells treated for 72 h. 1. U937; 2. THP-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. DNA fragmentation analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells were incubated with 40μmol/L  
ponicidin for 48 and 72 h. 
A: Control( no reagents were used)   
B: Cells treated for 48 h 
C: Cells treated for 72 h 
Lane1:U937 cell. Lane2:THP-1cell.  
M:Marker 
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4. Discussion 
 
Despite recent advances in our understanding of the molecular biology of leukemia cells and the 
induction of some new chemotherapeutic agents for the treatment of this malignant disease, there are 
few efficient therapeutic measures or regimes, especially for the patients who are in the mid-or final 
stages, and the dismal 5-year survival rate has not changed too much for this leading cause of cancer 
deaths in the world [7, 8]. Therefore, it is a permanent subject to find new drugs and effective therapies 
for the clinical treatment of leukemia. Plant-derived compounds are known to have curative potential. 
In this study, we found that ponicidin, a diterpenoid compound extracted from traditional Chinese 
herbs, could inhibit the proliferation by inducing apoptosis on leukemia U937 and THP-1 cells 
remarkably when the cells treated with different concentrations of ponicidin (over 10 μmol/L) for 
different times, and no significant cytotoxicity was found in the normal peripheral blood monocytes. 
Flow cytometry analysis showed that apoptotic cells gradually increased and the percentage of sub-G1 
cells of both U937 and THP-1 cells was over 60% after the cells were treated with 40 μmol/L 
ponicidin for 72 h, and the suppression was in both time-and dose-dependent manner. Marked 
morphological changes of cell apoptosis including condensation of chromatin and nuclear 
fragmentation were observed clearly by Hoechst 33258 staining especially after the cells were treated 
with ponicidin for 48~72 h, and typical DNA “ladder” was observed when apoptosis occurred. To 
clarify the mechanisms of apoptosis caused by ponicidin, we detected the expressions of both mRNA 
and protein levels of Survivin as well as Bcl-2 and Bax after the cells were treated with 40 μmol/L 
ponicidin for 48 and 72 h. RT-PCR and Western blot analysis revealed that both Survivin and Bcl-2 
expressions were down-regulated remarkably while Bax expression remained constant before and after 
apoptosis occurred.   
Apoptosis play an important role in the development and maintenace of homeostasis with all 
multicellular organisms, and impaired apoptosis is now recognized to be a key step in tumorigenesis 
[9]. Recently, inducers of apoptosis have been used in cancer therapy and activation of apoptosis 
pathways is a key mechanism by which cytotoxic drugs kill tumor cells [10]. All these studies indicate 
that induction of apoptosis can now be considered an important method of assessment for the clinical 
effectiveness of many anti-tumor drugs and a significant index for the selection of new anti-tumour 
drugs [10, 11]. Ponicidin is recently reported to be very effective in inducing growth inhibition and 
apoptosis in a variety of malignant cell lines. In this study, our results demonstrated that ponicidin has 
significant anti-proliferation effects by induction of apoptosis on leukemia U937 and THP-1 cells. The 
data suggest that ponicidin may be used as an effective apoptosis inducer on leukemia cells in vitro. 
These results have not been reported before. 
Survivin, a member of apoptosis inhibitor family, is expressed in most human malignancies and 
implicated in mitosis regulation and preservation of cell viability [12]. Previous data have revealed that 
survivin is one of the genes most consistently overexpressed in tumor cells which plays important roles 
in both cell proliferation and cell death [13]. Recent studies [14, 15] have shown that survivin is over 
expressed and is almost always present in leukemia cells, and expression of survivin always correlates 
with disease severity and over expression of survivin in tumor cells is a factor of poor prognosis in 
patients with leukemia. All these data suggest that this protein may play a role in leukemia 
tumourigenesis. Later studies have demonstrated that survivin is essential for cell cycle progression in Int. J. Mol. Sci. 2008, 9                 
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leukemia cells, and downregulation of survivin expression may lead to programmed cell death [16], 
indicating that survivin may be an appealing new target for novel therapies in leukemia [17].
  
The Bcl-2 family consists of about 20 homologues of important pro- and anti-apoptotic regulators 
of programmed cell death. Bcl-2 represents the founding member of the new and growing class of cell 
death inhibiting oncoproteins [18]. The first pro-apoptotic homolog of Bcl-2 family, Bax, was 
identified by coimmunoprecipitation with Bcl-2 protein. When Bax was overexpressed in cells, 
apoptotic death in response to death signals was accelerated, earning its designation as a death agonist. 
When Bcl-2 was overexpressed, it heterodimerized with Bax and death was repressed, thus the ratio of 
Bcl-2 to Bax is important in determining susceptibility to apoptosis [19, 20]. In this study, our results 
revealed that Bcl-2 expression was down-regulated remarkably in ponicidin induced apoptosis on 
leukemia cells. Though Bax expression remained constant before and after apoptosis ocurred, the ratio 
of Bcl-2 to Bax was downregulated, apoptosis therefore was induced in ponicidin treated leukemia cells. 
Though survivin and Bcl-2 are both apoptosis inhibitors, they function in the regulation of cell 
apoptosis through different pathways. Bcl-2 regulates apoptosis mainly by preventing cytochrome C 
release from mitochondrion to cytoplasm [18, 19], whereas survivin acts by direct inhibition of the 
terminal effector proteases of apoptosis. Studies have demonstrated that survivin could directly inhibit 
the activities of Caspase-3 and 7, and block the process of apoptosis [21]. Previous studies 
demonstrated that the expression of survivin was significantly associated with Bcl-2 expression and 
the expression of survivin, in conjunction with Bcl-2, might cause more pronounced anti-apoptotic 
effects [22, 23]. Therefore the expression of survivin in cooperation with Bcl-2 is a significant 
prognostic parameter and a new therapeutic target in cancer [24, 25]. These data indicated that the 
coexpression of survivin and Bcl-2 may play an important role in the regulation of cancer cell 
apoptosis. In the present study, we found that the expressions of both survivin and Bcl-2 were 
downregulated concurrently in ponicidin induced apoptosis on the two leukemia cell lines. Our results 
agree with the findings of previous investigations, which showed that the coexpressions of survivin 
and Bcl-2 play an important role in drug induced apoptosis [22, 23]. The data suggest that ponicidin 
may serve as a potential therapeutic agent for leukemia. The in vivo antitumor effects of ponicidin as 
well as its potential clinical effectiveness need further and profound investigation. 
 
5. Conclusions 
 
Ponicidin has significant anti-proliferation effects by inducing apoptosis on leukemia cells in vitro, 
downregulation of survivin as well as Bcl-2 expressions may be the important apoptotic inducing 
mechanisms. The results suggest that ponicidin may serve as potential therapeutic agents for leukemia. 
To our knowledge, this is the first report about the roles of ponicidin on monocytic leukemia cell in vitro. 
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